{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:35:38Z","timestamp":1785386138246,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.phrs.2020.105305","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T07:46:21Z","timestamp":1605339981000},"page":"105305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"164","author":[{"given":"Xumin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2361","authenticated-orcid":false,"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taowei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangpeng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengren","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-0606","authenticated-orcid":false,"given":"Xiangming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105305_bib0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2020.105305_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.9.2.211","article-title":"Androgen deprivation therapy for prostate cancer","volume":"9","author":"Singer","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2020.105305_bib0015","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.105305_bib0020","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.105305_bib0025","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1128\/AAC.05105-11","article-title":"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma\/cyst disposition, and efficacy in infected mice","volume":"55","author":"Ceballos","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2020.105305_bib0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.actatropica.2013.05.004","article-title":"A pharmacology-based comparison of the activity of albendazole and flubendazole against Echinococcus granulosus metacestode in sheep","volume":"127","author":"Ceballos","year":"2013","journal-title":"Acta Trop."},{"key":"10.1016\/j.phrs.2020.105305_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.parint.2009.07.006","article-title":"Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice","volume":"58","author":"Ceballos","year":"2009","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.phrs.2020.105305_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eri.11.30","article-title":"Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs","volume":"9","author":"Mackenzie","year":"2011","journal-title":"Expert Rev. Anti. Ther."},{"key":"10.1016\/j.phrs.2020.105305_bib0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14712\/18059694.2017.44","article-title":"Anthelmintic flubendazole and its potential use in anticancer therapy","volume":"60","author":"Canova","year":"2017","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"10.1016\/j.phrs.2020.105305_bib0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1871520618666171213141911","article-title":"The effect of flubendazole on adhesion and migration in SW480 and SW620 Colon Cancer cells","volume":"18","author":"Hanusova","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.phrs.2020.105305_bib0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/jphp.12503","article-title":"Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro","volume":"68","author":"Kralova","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105305_bib0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.105305_bib0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2017.10.020","article-title":"Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer","volume":"412","author":"Kim","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.105305_bib0070","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2020.105305_bib0075","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.105305_bib0080","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/srep08202","article-title":"Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen","volume":"5","author":"Michaelis","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.105305_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41420-017-0017-2","article-title":"Flubendazole inhibits glioma proliferation by G2\/M cell cycle arrest and pro-apoptosis","volume":"4","author":"Zhou","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.phrs.2020.105305_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.105305_bib0095","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.105305_bib0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CCO.0000000000000024","article-title":"To be, or not to be: functional dilemma of p53 metabolic regulation","volume":"26","author":"Wang","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.phrs.2020.105305_bib0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tcb.2011.10.006","article-title":"Deconstructing p53 transcriptional networks in tumor suppression","volume":"22","author":"Bieging","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2020.105305_bib0110","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","article-title":"Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression","volume":"145","author":"Brady","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.105305_bib0115","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.celrep.2013.04.012","article-title":"p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa","volume":"3","author":"Valente","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2020.105305_bib0120","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fphar.2020.00758","article-title":"Pyrimethamine elicits antitumor effects on prostate Cancer by inhibiting the p38-NF-kappaB pathway","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105305_bib0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.105305_bib0130","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.105305_bib0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2020.105305_bib0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: Death by Lipid Peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2020.105305_bib0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2478\/helm-2019-0029","article-title":"The influence of chestnut wood and flubendazole on morphology of small intestine and lymphocytes of peripheral blood, spleen and jejunum in broiler chickens","volume":"56","author":"Levkut","year":"2019","journal-title":"Helminthologia"},{"key":"10.1016\/j.phrs.2020.105305_bib0150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/OTT.S193206","article-title":"The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-kappaB signaling in esophageal squamous cell carcinoma","volume":"12","author":"Tao","year":"2019","journal-title":"Onco. Ther."},{"key":"10.1016\/j.phrs.2020.105305_bib0155","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/jcmm.13008","article-title":"Ferroptosis, a new form of cell death, and its relationships with tumourous diseases","volume":"21","author":"Yu","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2020.105305_bib0160","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1172\/JCI99490","article-title":"Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium","volume":"128","author":"Dar","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2020.105305_bib0165","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bbrc.2018.07.078","article-title":"Ferroptosis is a lysosomal cell death process","volume":"503","author":"Gao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.105305_bib0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-020-0149-3","article-title":"Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium\/calmodulin-dependent ferroptosis","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2020.105305_bib0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.105305_bib0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2045-3701-3-9","article-title":"The regulation of cellular metabolism by tumor suppressor p53","volume":"3","author":"Liang","year":"2013","journal-title":"Cell Biosci."},{"key":"10.1016\/j.phrs.2020.105305_bib0185","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.1001006107","article-title":"Glutaminase 2., A novel p53 target gene regulating energy metabolism and antioxidant function","volume":"107","author":"Hu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.105305_bib0190","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.1002459107","article-title":"Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species","volume":"107","author":"Suzuki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.105305_bib0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.105305_bib0200","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2013.06.019","article-title":"Metabolic regulation by p53 family members","volume":"18","author":"Berkers","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.105305_bib0205","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/15384101.2015.1068479","article-title":"Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses","volume":"14","author":"Jiang","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2020.105305_bib0210","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/sj.bjc.6602177","article-title":"Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer","volume":"91","author":"Birtle","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2020.105305_bib0215","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/oxfordjournals.annonc.a058938","article-title":"5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study","volume":"5","author":"Huan","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2020.105305_bib0220","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005247.pub2","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2020.105305_bib0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-1-61779-163-5_25","article-title":"Quantitative analysis of the enzymes associated with 5-fluorouracil metabolism in prostate cancer biopsies","volume":"755","author":"Tanaka","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2020.105305_bib0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2019.01.026","article-title":"Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer","volume":"448","author":"Fu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.105305_bib0235","first-page":"1385","article-title":"A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer","volume":"21","author":"Lin","year":"2001","journal-title":"Anticancer Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:19:05Z","timestamp":1760912345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820316133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":47,"alternative-id":["S1043661820316133"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105305","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105305"}}